Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) released its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.11), FiscalAI reports.

Acurx Pharmaceuticals Price Performance

ACXP stock traded down $0.06 during midday trading on Thursday, reaching $1.48. The company had a trading volume of 261,254 shares, compared to its average volume of 1,311,702. Acurx Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $8.34. The company has a market capitalization of $6.36 million, a P/E ratio of -0.37 and a beta of -2.03. The firm has a 50-day moving average price of $1.53 and a 200-day moving average price of $2.22.

Institutional Trading of Acurx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ACXP. Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals in the second quarter worth $551,000. Geode Capital Management LLC purchased a new stake in Acurx Pharmaceuticals during the fourth quarter valued at about $31,000. Jane Street Group LLC bought a new stake in Acurx Pharmaceuticals during the fourth quarter worth about $27,000. Finally, Millennium Management LLC bought a new stake in Acurx Pharmaceuticals during the fourth quarter worth about $103,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on ACXP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen upgraded shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Acurx Pharmaceuticals has an average rating of “Hold” and a consensus target price of $31.00.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).